GPRC5D-Targeted Therapies in Relapsed Multiple Myeloma: Real-World Results and Community Practice Challenges

home / training-academy / gprc5d-targeted-therapies-in-relapsed-multiple-myeloma-real-world-results-and-community-practice

Salman Fazal, MD; Yvonne Efebera, MD; Sumit Madan, MD, Ruemu Birhiray, MD, discuss how evaluating real-world efficacy and safety outcomes of GPRC5D-targeted therapies, along with identifying practical challenges and considerations, can guide the implementation of bispecifics in community practices.

4 KOLs are featured in this series.

EP. 1: GPRC5D-Targeted Therapies in Relapsed Multiple Myeloma

Salman Fazal, MD ;Yvonne Efebera, MD ;Sumit Madan, MD ;Ruemu Birhiray, MD
September 27th 2024

Panelists discuss how their clinical experience with GPRC5D bispecific therapies has been limited or nonexistent due to the novelty of these treatments in multiple myeloma.

4 KOLs are featured in this series.

EP. 2: Real-World Efficacy of GPRC5D Bispecifics vs Clinical Trials

Salman Fazal, MD ;Yvonne Efebera, MD ;Sumit Madan, MD ;Ruemu Birhiray, MD
September 27th 2024

Panelists discuss how GPRC5D bispecific therapies have shown promising efficacy in real-world relapsed/refractory multiple myeloma patients.

4 KOLs are featured in this series.

EP. 3: Patient Selection Factors for GPRC5D-Targeted Therapies

Salman Fazal, MD ;Yvonne Efebera, MD ;Sumit Madan, MD ;Ruemu Birhiray, MD
October 4th 2024

Panelists discuss how patient selection for GPRC5D-targeted therapies in the relapsed/refractory setting is guided by factors such as prior treatment history, including the number and types of previous therapies, with special consideration given to patients who have exhausted other options or shown resistance to earlier lines of treatment.

4 KOLs are featured in this series.

EP. 4: Patient Subgroup Outcomes with GPRC5D Bispecifics

Salman Fazal, MD ;Yvonne Efebera, MD ;Sumit Madan, MD ;Ruemu Birhiray, MD
October 4th 2024

Panelists discuss how certain patient subgroups, such as those with high-risk cytogenetics or extramedullary disease, may experience different outcomes with GPRC5D bispecific therapies, though more data is needed to draw definitive conclusions about subgroup-specific responses.